- Home
- / Rallybio
Rallybio
Stock Price
$1
2024-10-28
Market Capitalization
$43.1 M
2024-10-28
Revenue
$858 K
FY, 2025
Rallybio Summary
Company Summary
- Overview
- Rallybio is a clinical-stage biotechnology company developing drugs with the main focus on antibodies, small molecules, and engineered proteins. It develops the anti-HPA-1a antibody RLYB211 and RLYB212 therapies for patients with fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- New Haven, CT, US | view all locations
- Website
- https://rallybio.com/
- Cybersecurity rating
Table of Contents
LocationsView all
2 locations detected
New Haven, CT HQ
United States
234 Church Street, Suite 1020
Farmington, CT
United States
400 Farmington Avenue, Suite R2818
Rallybio Financials
Summary Financials
- Revenue (Q1, 2026)
- $212.0K
- Net income (Q1, 2026)
- ($8.3M)
- Cash (Q1, 2026)
- $41.3M
- EBIT (Q1, 2026)
- ($8.7M)
- Enterprise value
- $2.0M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026